Skip to main content
Clinical Trials/NCT05902806
NCT05902806CompletedNot Applicable

Evaluation of the Gastro-intestinal Tolerance, Nutritional Intake, and Acceptability of an Upgraded Composition of an Enteral Tube Feed for Adults in Need of Long Term Nutritional Support (Peacock Butterfly)

Nutricia Research2 sites in 1 country101 target enrollmentStarted: May 23, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
101
Locations
2
Primary Endpoint
Gastro-intestinal tolerance

Study Overview

Brief Summary

This study evaluates the gastro-intestinal tolerance, nutritional intake, and acceptability of an upgraded composition of an enteral tube feed for adults in need of long term nutritional support.

Detailed Description

Four current tube feed products are upgraded with the same product composition and will be investigated in this study. Subjects will be asked to continue with their current tube feeding for 7 days (baseline period) and asked to complete a daily gastro-intestinal tolerance questionnaire. On Day 8, the subjects will switch to one of four upgraded tube feeding products for 14 days (intervention period). The subjects are asked to complete the same gastro-intestinal tolerance questionnaire for again 7 days. On Day 21 (end of intervention), the subjects will return to their original tube feed product and the investigator will follow up on how they are feeling to evaluate tolerability and product acceptability.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 years
  • Using either an enteral tube feed with approximately 1.0 or 1.5 kcal/mL with or without fibers via a nasogastric tube (NGT), nasojejunal (NJT) or Percutaneous Endoscopic Gastrostomy (PEG) for at least 4 weeks prior to screening
  • Actual and expected average daily intake of enteral nutrition at least 1000 kcal for at least 21 days after the start of baseline period
  • Written informed consent from subject (or impartial witness after verbal consent of subject)

Exclusion Criteria

  • 1. Subjects receiving total parental feeding (TPN)
  • Gastro-intestinal surgery or any other surgery involving general anaesthesia within 2 weeks prior to screening
  • Subjects with major hepatic or renal dysfunction in the opinion of the Investigator
  • Subjects currently in the intensive care unit
  • Active/flare up condition of chronic illnesses in small or large intestines in the opinion of the Investigator (e.g., active inflammation/flare up of Crohn's disease or ulcerative colitis) within 2 weeks prior to screening,
  • Subjects experiencing cancer treatment-related diarrhea within 2 weeks prior to screening
  • Presence of colostomy or other faecal diversion
  • Known intolerance or allergy to ingredients of study product (e.g. galactosemia, allergy to soy)
  • Inability of the subject to answer the study diary or questionnaires due to e.g., being unconscious, cognitive impairment, or dementia, in the opinion of the Investigator
  • Known pregnancy or lactation
  • Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
  • Active participation in any other clinical study involving investigational or marketed products concomitantly or within four weeks prior to entry into the study in the opinion of the Investigator

Arms & Interventions

Comparison of current tube feed to intervention feed with upgraded composition

Experimental

Subjects will use their own current practice tube feed for 1 week (baseline period) and will switch to the intervention tube feed with an upgraded composition with a comparable energy density and fiber content as their current tube for 2 weeks (intervention period). Since four different products will be evaluated (product A-D), there will be 4 study groups

Intervention: Upgraded tube feed (Dietary Supplement)

Outcomes

Primary Outcomes

Gastro-intestinal tolerance

Time Frame: 7 days in the second week of the 2-week intervention period

self-reported GI symptoms with a GI symptom questionnaire

bowel movement pattern

Time Frame: 7 days in the second week of the 2-week intervention period

Self reported bowel movement pattern with the 7-point Bristol Stool Form Scale (BSFS) ranging from "1" (indicating separate, hard lumps) to "7", which stands for entirely liquid, watery stool without any hard components

Secondary Outcomes

  • Use of complementary feeding with a questionnaire ((use of normal foods, oral nutritional supplements, parenteral feeding: Yes/No)(7 days in the 1-week baseline period, 7 days in the first week of the 2-week intervention period, and 7 days in the second week of the 2-week intervention period (i.e., on a daily basis during the entire study duration).)
  • Volume of tube feed administration(7 days in the 1-week baseline period, 7 days in the first week of the 2-week intervention period, and 7 days in the second week of the 2-week intervention period (i.e., on a daily basis during the entire study duration).)
  • Difference between prescribed volume of tube feed administration by Health Care Professional and actual daily self-reported administrated volume of tube feed(7 days in the 1-week baseline period, 7 days in the first week of the 2-week intervention period, and 7 days in the second week of the 2-week intervention period (i.e., on a daily basis during the entire study duration).)
  • Product acceptability with a questionnaire(Day 21 (end of intervention period regarding the upgraded tube feed))
  • Anthropometrics(Intervention Day 21)

Investigators

Sponsor
Nutricia Research
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials